University of Cambridge Enterprise Fund
The University of Cambridge Enterprise Fund is not currently fundraising. A similar fund, which Parkwalk also manages, Parkwalk Opportunities EIS is open for investment. The fund invests in university spinouts mainly from the universities of Oxford, Cambridge, and Bristol.
Alternatively, you can register below to receive an alert when the University of Cambridge Enterprise Fund opens. This is not expected until early 2020.
Receive an alert when the University of Cambridge Enterprise Fund opens
This fund is a partnership between Parkwalk Advisors and Cambridge Enterprise.
- Experienced portfolio manager
- Exclusive deal flow from the University of Cambridge
- Co-investment opportunities with institutional investors, including parent company IP Group
- Minimum investment usually £25,000
This fund is managed by Parkwalk with Cambridge Enterprise as the Portfolio Advisor.
The fund will be managed by Parkwalk, an experienced and award-winning EIS fund manager. Founded by Alistair Kilgour and Moray Wright, Parkwalk is the UK’s most active investor into the university spin-out sector. The companies in which it has invested have raised over £1 billion in fundraising since 2010. This has been achieved through its relationships with UK Russell Group Universities and increased resourcing after a merger with IP Group, a leading IP commercialisation company.
Cambridge University is a hub for research and innovation. The university has a pedigree spanning over 800 years and has been home to over 100 Nobel Prize winners and discoveries such as stem cell research and IVF.
Cambridge Enterprise was launched in 2006 to help commercialise ideas and inventions developed within the university. Its creation has helped the university spin out over 200 companies in the last two decades, 15 of which are now individually worth over $1 billion. As the portfolio advisor, Cambridge Enterprise will source and evaluate appropriate opportunities for the fund.
Cambridge Enterprise sources its deal flow through two main routes, Technology Transfer and Seed Funds. The Technology Transfer team helps academics develop and progress their research into viable commercial opportunities. Whereas the Seed Funding team focuses on creating new companies based on technology already owned by the university or its members.
Deals are only selected if the idea or invention has the potential to be commercially attractive to businesses or investors. During the initial due diligence process, Cambridge Enterprise will assess the technical and commercial aspects of the opportunity. Typically, this will include looking for existing competitors or patents as well as measuring industry interest.
If an opportunity is selected, Cambridge Enterprise will support the company continuously through its development. This can be from its initial patent application all the way to assisting in final sale negotiations.
Prospective companies will be assessed by Parkwalk before being included within the Cambridge Innovation Fund. As with any Parkwalk fund, the companies must be able to demonstrate proven technology and should address a significant issue.
Risks – important
This, like all investments available through Wealth Club, is only for experienced investors happy to make their own investment decisions without advice.
EIS investments are high risk so should only form part of a balanced portfolio and you should not invest money you cannot afford to lose. They also tend to be illiquid and hard to sell and value. Before you invest, please carefully read the Risks and Commitments and the offer documents to ensure you fully understand the risks.
Tax rules can change and benefits depend on circumstances.
This EIS fund invests in early-stage businesses which are more likely to fail than larger ones, so you should expect a number of failures in the portfolio.
Wealth Club aims to make it easier for experienced investors to find information on – and apply for – tax-efficient investments. You should base your investment decision on the provider's documents and ensure you have read and fully understand them before investing. This review is a marketing communication. It is not advice or a personal or research recommendation to buy the investment mentioned. It does not satisfy legal requirements promoting investment research independence and is thus not subject to prohibitions on dealing ahead of its dissemination.
- University spinouts
- Target return
- Funds raised / sought
- Minimum investment
- Coming soon